The pooled hazard ratio of EGFR-TKI/chemotherapy for PFS was 0.28 (95% CI=0.20–0.38, P<0.001) in patients with NSCLC positive for exon 19 deletion and 0.47 (95% CI=0.35–0.64, P<0.001) in those with NSCLC positive for exon 21 L858R mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.